Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Topscience Biotech specializes in R&D, production, sales of Sodium Hyaluronate, focusing on Cosmetics, Medical, Pharmaceutical Grade HA

    Virtual Booth

    Contact Supplier

    Alchem offers Phytochemical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    China

    Virtual Booth

    Contact Supplier

    Menu

    Lorundrostat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 247,857Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mineralys Therapeutics Announces Late-Breaking Data Presentation
    Mineralys Therapeutics Announces Late-Breaking Data Presentation

    24 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/24/3087776/0/en/Mineralys-Therapeutics-Announces-Late-Breaking-Presentation-of-Data-from-the-Launch-HTN-Pivotal-Trial-of-Lorundrostat-in-Uncontrolled-or-Resistant-Hypertension-at-34th-European-Mee.html

    GLOBENEWSWIRE
    24 May 2025
    Share Share
    Mineralys Therapeutics Announces Ph 2 Advance-HTN Results in NEJM
    Mineralys Therapeutics Announces Ph 2 Advance-HTN Results in NEJM

    23 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/23/3066971/0/en/Mineralys-Therapeutics-Announces-Publication-of-Pivotal-Phase-2-Advance-HTN-Results-in-the-New-England-Journal-of-Medicine-NEJM.html

    GLOBENEWSWIRE
    23 Apr 2025
    Share Share
    Mineralys Reports Late-Breaking Data From Advance-HTN Trial
    Mineralys Reports Late-Breaking Data From Advance-HTN Trial

    29 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/29/3051760/0/en/Mineralys-Therapeutics-Announces-Late-Breaking-Data-from-Advance-HTN-Pivotal-Trial-of-Lorundrostat-in-Uncontrolled-and-Resistant-Hypertension-Presented-at-the-American-College-of-C.html

    GLOBENEWSWIRE
    29 Mar 2025
    Share Share
    Mineralys Reports Positive Ph3 Lorundrostat Data In Hypertension
    Mineralys Reports Positive Ph3 Lorundrostat Data In Hypertension

    10 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/10/3039559/0/en/Mineralys-Therapeutics-Announces-Positive-Topline-Results-from-Launch-HTN-and-Advance-HTN-Pivotal-Trials-of-Lorundrostat-for-the-Treatment-of-Uncontrolled-or-Resistant-Hypertension.html

    GLOBENEWSWIRE
    10 Mar 2025
    Share Share
    Mineralys Completes Enrollment in Explore-CKD Ph 2 for Hypertension
    Mineralys Completes Enrollment in Explore-CKD Ph 2 for Hypertension

    04 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/04/3020225/0/en/Mineralys-Therapeutics-Completes-Enrollment-in-Explore-CKD-Phase-2-Trial-of-Lorundrostat-for-the-Treatment-of-Hypertension-in-Subjects-with-Stage-2-to-3b-CKD-and-Albuminuria.html

    GLOBENEWSWIRE
    04 Feb 2025
    Share Share
    Mineralys Completes Enrollment in Lorundrostat Hypertension Trial
    Mineralys Completes Enrollment in Lorundrostat Hypertension Trial

    30 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/30/2971654/0/en/Mineralys-Therapeutics-Completes-Enrollment-Ahead-of-Schedule-in-Launch-HTN-the-Second-Pivotal-Trial-of-Lorundrostat-for-the-Treatment-of-Hypertension.html

    GLOBENEWSWIRE
    30 Oct 2024
    Share Share